Reports of Injection Site Necrosis After 23-Valent Pneumococcal Vaccine Use

Brendan Day; Deborah Thompson; Adamma Mba-Jonas; Meghna Alimchandani

doi:10.1001/jamainternmed.2023.2146

Reports of Injection Site Necrosis After 23-Valent Pneumococcal Vaccine Use

JAMA Intern Med. 2023 Sep 1;183(9):1015-1016. doi: 10.1001/jamainternmed.2023.2146.

Authors

Brendan Day¹, Deborah Thompson¹, Adamma Mba-Jonas¹, Meghna Alimchandani¹

Affiliation

¹ Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.

PMID: 37399033
PMCID: PMC10318545 (available on 2024-07-03)
DOI: 10.1001/jamainternmed.2023.2146

No abstract available

Plain language summary

This case series uses postmarketing data to evaluate the incidence of injection site necrosis after 23-valent pneumococcal vaccine use in the global market.

MeSH terms

Humans
Infant
Necrosis
Pneumococcal Infections* / prevention & control
Pneumococcal Vaccines / adverse effects
Streptococcus pneumoniae*

Substances

Pneumococcal Vaccines